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Purpose: RNA and DNA sequencing data are traditionally used to discern intrinsic 
cellular pathways in cancer pathogenesis, their utility for investigating the tumor microen-
vironment (TME) has not been fully explored. This study explores the use of sequencing 
data to investigate immunity within the TME.
experimental design: Here, we use immune cell fraction estimation analysis to deter-
mine the immune profiles in the microenvironment of neuroblastoma (NB) based on 
RNA-seq data in the TARGET database. The correlation between immune cell transcripts 
and prognosis in pediatric NB is also investigated.
results: In silico analysis revealed a strong inverse correlation between MYCN ampli-
fication and leukocyte infiltration. This finding was validated by immunohistochemistry 
analysis in tumor samples. Moreover, the abundance of CD4 T cells strongly associated 
with better patient survival regardless of MYCN gene amplification, while those of CD8 
T cells, NK or B cells do not. Based on characteristic cytokine expression of CD4 subsets 
in tumors, the Th2 rather than Th1 levels were associated with better prognosis.
conclusion: We found that the in silico analysis of TARGET database reflected tumor 
immunity and was validated by the immunohistochemical tumor data. Our results reveal 
the association of MYCN amplification with repressed cellular immunity and the poten-
tial prognostic value of infiltrating CD4 T cell transcripts in pediatric NB. This analysis 
illustrates the potential role of MYCN in NB as a regulator of immune privilege and 
characterizes the power of in silico analysis for delineating cancer immunology and risk 
stratification.
Keywords: MYCN, immunesuppression, neuroblastoma, cellular immunity, in silico analysis
inTrODUcTiOn
Neuroblastoma (NB) is among the most common cancers in childhood. More than 90% of NB 
are diagnosed prior to 5 years of age, in which the prognosis of NB varies greatly based on risk 
stratification (1–3). While >90% of patients with intermediate and low-risk tumors survive 5 years 
or more, only 40–50% of patients with high-risk NB achieve 5-year survival (4). Risk stratification 
Table 1 | Baseline characteristics of the patients.*











Mean ± SEM 1,037.52 ± 162.672 1,303.18 ± 101.853 ns (0.22)
sex—no. (%)
Male 18 (58.1) 69 (59.0) ns (>0.99)
Female 13 (41.9) 48 (41.0) ns (>0.99)
cOg risk group—no. (%)
High risk 31 (100.0) 91 (77.8) Significant 
(0.0024)
Intermediate risk 0 (0.0) 13 (11.1) ns (0.07)
Low risk 0 (0.0) 13 (11.1) ns (0.07)
*P-values were calculated by using two-tailed Student’s t-test (age at diagnosis) and 
Fisher’s exact test [sex and Children’s Oncology Group (COG) risk Group].
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is based on genetic alterations, histological findings as well as age 
of diagnosis among other clinical factors. While MYCN amp-
lification and unbalanced 11q aberration have emerged as the 
dominant factors in risk assignment (5), poorly differentiated 
or undifferentiated ganglioneuroblastoma, and NB without these 
genetic alterations can also show poor prognosis. It is therefore 
of interest to search for other shared features of high-risk NB 
identified by either histology or genetic risk profiles.
The theory of immune surveillance, as originally proposed by 
Burnet, predicts that immune response is a key determinant of 
cancer risk (6). In a 1972 study of histologic lymphocytic infil-
tration in 23 primary NBs, a positive correlation with survival 
was found in infancy and childhood (7). Through extensive 
investigations, it is established in a number of other tumor types 
that components of immune infiltration into the tumor plays 
a critical role in cancer prognosis. However, these analyses are 
difficult to standardize, thus it has not been feasible to use them 
as markers for risk assignment in cancer prognosis.
Whole genome sequencing of tumor samples is now routinely 
performed for cancer samples. The wealth of data collected from 
these studies allows one to unveil molecular pathogenesis of 
cancer cells. Since host inflammatory cells are now considered 
an integral part of the tumor microenvironment (TME), it is 
inevitable that deep sequencing of cancer tissues will also capture 
information of inflammatory cells. CIBERSORT is a recently 
reported computational approach that uses gene expression 
profiles to estimate relative fractions of diverse cell subsets in 
complex tissues, including tumors (8, 9). The power of this 
algorithm in delineating immune composition of tumor tissues 
prompted us to test whether one can use the bulk of next genera-
tion sequencing data already collected to evaluate the potential 
role of immunity in determining prognosis in NB, a tumor with 
well-defined risk stratification. Here, we report our use of this 
program to analyze TARGET data matrix for NB in which we 
found that CD4 T  cell signature significantly associates with 
prognosis of NB in both MYCN amplified and non-amplified 
tumors. We also observed the unexpected association between 
MYCN gene amplification and lack of inflammatory profiles 
suggesting the impact of MYCN gene amplification in repress-
ing NB host immunity. These findings were verified by selective 
immunohistochemistry in patient samples. Furthermore, these 
data show the power of in  silico analysis for cancer immunol-
ogy and raises the intriguing possibility of assigning cancer risk 
based on nextgen RNA-seq data.
MaTerials anD MeThODs
Data source
The TARGET initiative provides sequencing data and de- 
identified clinical information of cancer patients (available 
through the TARGET Data Matrix1). The current studies utilized 
database of genotypes and phenotypes via accession phs000471. 
A total of 148 NB patients were included based on availability 
detailed RNA-seq FPKM data, survival time after diagnosis, 
1 http://target.nci.nih.gov/dataMatrix/TARGET_DataMatrix.html.
risk assignment, and MYCN-amplification status. The demo-
graphy, risk stratification of NB with or without MYCN amplifica-
tion were summarized in Table 1.
immune cell Fraction estimation analysis
The online analytic tool, CIBERSORT (Cell type Identification 
By Estimating Relative Subsets Of known RNA Transcripts), was 
used according to the instruction provided by the developers.2 
LM22, a validated leukocyte gene signature matrix, was used 
here as a gene signature matrix. LM22 contains 547 genes that 
distinguish 22 human hematopoietic cell phenotypes. The gene 
expression data from the NB patients in TARGET database 
(n =  148) were input as a Mixture file and 500 permutations 
were performed. The percentage data of 22 immune cell types 
in each patient were transferred into the cell fraction of tumor 
by normalization with the ratio of CD45 and ACTB expression 
value. Additionally, 22 human hematopoietic cell phenotypes 
were merged into 16 immune cell types as follows: naive and 
memory B cells were merged into B cells; naïve, memory, resting, 
and activated CD4 T cells were merged into CD4 T cells; NK cells 
resting and NK cells activated were merged into NK cells; den-
dritic cells resting and dendritic cells activated were merged into 
DC cells; while mast cells resting and mast cell activated were 
merged into mast cells.
stratification of subgroups based  
on expression and Fraction Data
For CD45 expression, the NB samples were divided into CD45hi 
and CD45lo groups with the threshold (FPKM  =  7.5) based 
on its bimodal distribution of RNA-seq data (Figure S1A in 
Supplementary Material). Gene expression levels were normal-
ized based on actin expression and samples were divided into 
higher ratio (above the upper quartile) and lower ratio (below 
the lower quartile) groups based on RNA-seq data. For other 
parameters, the samples were divided into lower cell fraction 
(below the fraction value of peak) and higher cell fraction (above 
the twofold of fraction value of peak) groups based on their data 
2 https://cibersort.stanford.edu/.
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distribution of estimated cell fraction (T cells CD4 cell fraction 
distribution shown in Figure S1B in Supplementary Material).
gene set enrichment analysis (gsea)
Gene set enrichment analysis version 2.3.03 was performed 
with the JavaGSEA application using the following parameters: 
number of permutations =  1,000, permutations of phenotype, 
curated KEGG gene sets from MSigDB as gene sets database 
input. Significant enrichment was defined as those lists with >30 
genes and a false discovery rate <0.05.
specimens
Tumor specimens were obtained from 15 patients diagnosed 
with low (n = 3), intermediate (n = 6), and high (n = 6) risk NB. 
Diagnosis and staging were performed according to Children’s 
Oncology Group protocols. Biopsies were taken at the time of 
diagnosis and prior to initiation of any therapy. Specimen col-
lection was obtained with the appropriate research consent 
(and assents when applicable) and was approved by the Institu-
tional Review Board, CNMC, Washington D.C. (Pro00004284).
immunohistochemical analysis
Five-micron paraffin tissue sections were deparaffinized in 
xylene and rehydrated in 100 and 95% ethanol. Endogenous 
peroxidase activity was blocked by treating with 0.3% hydrogen 
peroxide for 30 min followed by phosphate-buffered saline (PBS) 
washing for 5  min. Sections were incubated overnight at 4°C 
with primary antibodies diluted in blocking buffer (PBS with 
5% serum). The following primary antibodies were used: CD4 
(rabbit monoclonal antihuman IgG, 1:150, abcam, Cambridge, 
MA, USA); CD45 (mouse monoclonal antihuman IgG1, abcam). 
Isotype-matched antibodies were used for negative controls. 
After washing with PBS, each section was incubated with 1:200 
diluted biotinylated secondary antibodies (Vector Laborato-
ries, Inc., Burlingame, CA, USA) for 1 h at room temperature. 
Secondary antibody was detected with Vectastain ABC reagent 
(ABC Elite Kit; Vector Laboratories), and 3′3′diaminobenzidine 
substrate (Sigma). Slides were washed in tap water for 5  min 
and then counterstained with hematoxylin (Sigma) for 30  s. 
Following counterstaining, slides were washed in tap water for 
5 min, dehydrated (95 and 100% ethanol), transferred to 100% 
xylene, and mounted. Brightfield immunohistochemical images 
were acquired with a Nikon Eclipse E800 microscope (Nikon 
Corp.). Images were taken at magnifications of ×100.
Quantitative analysis of cD4 and cD45 
expression in human Tissue
Thirty to forty randomly selected fields in each stained speci-
men were imaged under ×100 magnification. Quantification of 
positive staining intensity was achieved using Olympus cellSens 
imaging software (version 1.7). The positive staining intensity 
and the area of tumor tissue were measured. The positive staining 
intensity in each field was measured using a manual threshold 
setting. Measurements were made by the same person who was 
3 http://www.broadinstitute.org/gsea.
blinded to the clinical stage or characteristics of the tumor speci-
men. Data are presented as the mean positive staining intensity 
of all the fields for each specimen.
biostatistics
The specific tests used to analyze each set of experiments are 
indicated in the figure legends. Data were analyzed using an 
unpaired Mann–Whitney test to compare between two groups, 
and χ2 test for contingency table. In the graphs, y-axis error 
bars represent SEM as indicated. Statistical calculations were 
performed using GraphPad Prism software (GraphPad Software, 
San Diego, CA, USA) or R Software.4
resUlTs
MYCN amplification is associated with 
reduced inflammation in nb
To determine whether the increased risk is associated with 
either reduced immune response or increased resistance to it, 
we tested whether the inflammatory response is associated with 
MYCN amplification among patients in the TARGET database. 
The patients with or without MYCN amplification are similar 
in age at diagnosis, gender distribution (Table 1). We chose the 
transcript levels of the CD45 genes that is the marker for all leu-
kocytes, among MYCN amplified or non-amplified NB tumors. 
As shown in Figure  1A, after normalizing against ACTINB 
transcripts, MYCN amplified NB had significantly lower levels 
of CD45 transcripts, indicating reduced inflammation in MYCN 
amplified NB. To determine whether MYCN affects specific 
subset of leukocytes, we used the CIBERSORT algorithm to 
estimate the percentage of each leukocyte subset, focusing on the 
major cell types that can be identified by CIBERSORT. Among 
the major immune effector cells, including T, B, macrophages, 
dendritic cells, and NK cells, we found a general reduction of all 
leukocytes in MYCN-amplified samples (Figure 1B). The strong 
inverse correlation suggests that MYCN amplification in cancer 
cells has a profound impact on host immune response to NB.
While poor prognosis MYCN-amplified NB is well accepted 
and clearly demonstrable in the TARGET sample cohort 
(Figure  2A), the risk of MYCN non-amplified samples is 
traditionally stratified by a comprehensive list of clinical, patho-
logical, and molecular criteria. To determine if the abundance 
of CD45 transcripts can be used as a single parameter for NB 
risk stratification in MYCN non-amplified NB, we evaluated 
if CD45 levels associate with risk in this subgroup. As shown 
in Figure 2B, samples with more abundant CD45 show better 
survival, but the difference between CD45hi and CD45lo samples 
was not statistically significant. The hazard ratio (HR) and 
separation of the two groups suggest that lack of statistical 
significance may be due to a limited number of CD45hi samples 
as the TARGET samples are biased toward high-risk group 
stratification. Combining MYCN non-amplification and CD45hi 
parameters identified a group of NB patients with better survival 
(HR = 0.49, P = 0.03) (Figure 2C).
4 https://www.r-project.org/.
FigUre 2 | Tumor inflammation, combined with MYCN amplification is associated with neuroblastoma (NB) prognosis. (a) Kaplan–Meier curves showing 5-year 
survival of NB patients associated with MYCN amplification status. (b) Kaplan–Meier curves showing 5-year survival of NB patients assessed by CD45 expression. 
CD45lo and CD45hi subgroups were defined based on FPKM distribution as detailed in Section “Materials and Methods.” (c) Kaplan–Meier curves showing 5-year 
survival of NB patients according to the combination of MYCN amplification status and CD45 expression subtypes. The hazard ratio and P-value in (a,b,c) 
displayed on the graphs are from the log-rank test and Gehan–Breslow–Wilcoxon method.
FigUre 1 | MYCN amplification in neuroblastoma (NB) affects inflammatory immune cell phenotypes. (a) MYCN-non-amplified NB samples had greater 
inflammatory status as defined by CD45 expression (upper panel) and CD45/actin expression ratio (lower panel). (b) The relative abundance of six immune cell types 
was greater in MYCN-non-amplified tumors than in MYCN-amplified tumors. Statistical significance in (a,b) was determined using Mann–Whitney test.
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abundance of cD4 T cells in nb as a 
biomarker for Overall survival
As the first test to determine whether T cells play a significant 
role in NB prognosis, we compared the overall survival of the 
NB patients with the highest 25% or the lowest 25% levels of 
the gene transcript. While the CD8Bhi and CD8Blo NB patients 
show nearly identical overall survival (Figure  3A), the CD4hi  
NB patients have significantly better survival (Figure 3B).
To confirm whether the abundance of CD4 or CD8B cell tran-
scripts can be used as surrogate markers for the abundance of 
T cell subsets, we performed regression analysis of the transcript 
levels for the CD4 and CD8 T cells. As shown in Figure 4A, the 
levels of CD4 transcripts strongly correlated with the fraction 
of CD4 T  cells among all leukocytes. Likewise, the levels of 
CD8 transcripts strongly associates with the CD8 cell fraction 
(Figure 4B). To determine whether a specific leukocyte popu-
lation may be associated with overall survival, we divided the 
samples into high- and low-populations based on the relation-
ship with peak values. Those below peak value are assigned as 
the low subsets, while those that are 3-fold of the peak value are 
FigUre 3 | CD4 gene expression in the tumor is the principal determinant of prognosis in all patients and in patients with MYCN non-amplified tumors.  
(a) Kaplan–Meier curves showing 5-year survival of neuroblastoma (NB) patients according to their CD4 gene expression normalized to the ratio of actin  
expression. Total NB samples (left) and MYCN non-amplified NB samples (right) were divided into CD4/ACTBhi (above the upper quartile) and CD4/ACTBlo (below 
the lower quartile) groups based on RNA-seq data. (b) Kaplan–Meier curves showing 5-year survival of NB patients according to their CD8B gene expression 
normalized with the ratio of actin expression. Total NB samples (left) and MYCN non-amplified NB samples (right) were divided into CD8B/ACTBhi (above the upper 
quartile) and CD8B/ACTBlo (below the lower quartile) groups based on RNA-seq data. The hazard ratio and P-value in (a,b) displayed on the graphs are from the 
log-rank test and Gehan–Breslow–Wilcoxon method.
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defined as the high subset. As shown in Figure 4C, patients with 
the CD4 T cellshi subsets in the tumor have much better overall 
survival than those with the CD4 T  cellslo subset. In contrast, 
patients with the CD8 T cellshi subset had similar overall survival 
to that of CD8 T cellslo subset (Figure 4D).
We performed selective immunohistochemistry analysis of 
NB samples to confirm the key findings of the above in  silico 
analyses. As shown in Figures  5A,B, all MYCN-amplified 
samples analyzed had minimal infiltration of CD4 T  cells. 
While high-risk MYCN non-amplified NB are similar in CD4 
T  cell infiltration, intermediate, and low-risk NB had variable 
amounts of CD4 T cells infiltrates. As expected, the pattern of 
CD45 staining is similar to the CD4 T cells (data not shown). 
When the staining of CD45 and CD4 was integrated digitally, 
it is clear that high-risk NB samples (including MYCN ampli-
fied and non-amplified) had reduced CD4 and CD45 staining 
(Figure 5C). These data validated the in silico analysis.
immunological Mechanism of Protection 
by cD4 T cells
To understand the possible mechanism by which increased 
CD4 T  cells confer protection for NB patients, we performed 
Kegg pathway analysis to identify enhanced pathway in the 
samples in high-CD4 transcripts. The top 10 pathways are listed 
in Figure  6A and examples of the association are shown in 
Figure 6B. Chief among them include FcRγ-mediated phago-
cytosis, NK cell-mediated cytotoxicity, cell adhesion molecules, 
and T cell signaling. These data suggest that CD4 T cells likely 
promote cancer rejection by orchestrating innate immune effec-
tors within the TME.
CD4 T  cells can be divided into regulatory and effector 
T  cells. Since our preliminary analysis suggest no correlation 
between Treg subsets (data not shown), we focused on effector 
CD4 cells. CD4 T  cells differentiated into multiple functional 
subsets including Th0, Th1, Th2, Th9, and Th17 among others, 
FigUre 4 | CD4 cell abundance is the principal determinant for prognosis in patients with MYCN non-amplified tumors. (a) Dot plot showing the correlations 
between CD4 gene expression normalized with the ratio of actin expression and CD4 T cell relative abundance. (b) Dot plot showing the correlations between 
CD8B gene expression normalized with the ratio of actin expression and CD8 T cell relative abundance. (c) Kaplan–Meier curves showing 5-year survival of 
neuroblastoma (NB) patients with MYCN non-amplified tumors according to their CD4 T cell relative abundance. (D) Kaplan–Meier curves showing 5-year survival  
of NB patients with MYCN non-amplified status according to their CD8 T cell relative abundance. NB samples were divided into Relative Abundancehi and Relative 
Abundancelo groups, respectively, based on the immune cell relative abundance data as detailed in Section “Materials and Methods.”. Correlation coefficient and 
P-value in (a,b) were determined using Spearman method. The hazard ratio and P-value displayed on the graphs are from the log-rank test and Gehan–Breslow–
Wilcoxon method.
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each characterized by their cytokine profiles and their master 
transcriptional regulators. Since most master regulators are 
prominently expressed in cancer cells, we decide to use their 
characteristic cytokines to discern the functional subsets associ-
ated with NB prognosis. As shown in Figures 6C–E, IL-2 (Th0), 
IFNγ, and TNFα (Th1) transcript levels showed no statistically 
significant association with NB prognosis. Surprisingly, IL-4 
transcript levels were significantly associated with NB prognosis 
(P = 0.05).
DiscUssiOn
Neuroblastoma is the most common extra-cranial solid tumor 
found in children and continues to have a poor prognosis in 
cases of high-risk disease despite multimodal therapy (10–12). 
Risk stratification is well defined in NB which predicts patient 
outcome, but is also used to guide therapy. Risk stratification is 
based on molecular, pathologic, and clinical findings, but there 
are no immunologic parameters that are considered in defining 
tumor risk (3). As immunotherapy in the form of either targeted 
antibodies or checkpoint inhibitors is changing cancer treat-
ment, understanding the immune environment could be critical 
to both risk stratification, and application of immunotherapy. 
Using in  silico analysis from a sequence database, we inves-
tigated NB from the perspective of immune cell transcript 
infiltrates and the association with outcome. It was clear that 
CD4 transcripts were associated with better outcomes in which 
a high transcript was associated with improved survival. This 
correlated with immunohistochemistry for CD4 cellular infil-
trates in which tumors with poor prognosis and high risk had a 
lower CD4 cellular infiltrate in tumors. Though it is established 
in a number of tumor types that components of immune infil-
tration into the tumor plays a critical role in cancer prognosis 
(13–18), standardizing cellular infiltrates has been difficult and 
thus application for risk stratification has not been practical. 
Analyzing transcripts in sequence data may offer a method for 
standardizing cellular infiltrates for use in risk assignment for 
cancer prognosis.
MYCN amplification in NB is the most important molecular 
biomarker categorizing tumors in the high-risk category. Irres-
pective of all other clinical, molecular, or biomarkers, if MYCN 
is amplified in the tumor it is categorized as high risk. In our 
analysis, MYCN amplified NB had significantly lower levels of 
CD45 transcripts, indicating reduced inflammation in MYCN 
amplified tumors. All the transcripts of major immune effector 
cells, including T  cells, B  cells, macrophages, dendritic cells, 
FigUre 5 | Immunohistochemical analysis of leukocyte infiltration in neuroblastoma (NB). (a) Immunohistochemical staining of CD4 (brown) and CD45 (data not 
shown) was performed on paraffin embedded NB tumor tissue at diagnostic biopsy from MYCN amplified high-risk, MYCN non-amplified high-risk, MYCN 
non-amplified intermediate, and MYCN non-amplified low-risk tumors. The nuclei were counterstained with hematoxylin (blue). Tissue sections were imaged at ×100 
original magnification. The association between CD4, CD45 expression, and MYCN amplification (b) and risk stratification (c) was determined by digital mean 
density image analysis and the data are graphed. P-values in (c) were calculated with an unpaired Mann–Whitney test.
FigUre 6 | Immunological mechanisms underlying the association between CD4 T cells and prognosis of neuroblastoma (NB) patients. (a) Top 10 significant 
KEGG pathways enriched in NB samples with CD4hi. The normalized enrichment score normalized P-value and false discovery rate are displayed on the graphs.  
(b) Gene set enrichment analysis enrichment plot showing significant enrichment of upregulated pathways (Fc gamma R-mediated phagocytosis; left, T cell 
receptor; right) in NB samples with CD4hi. (c–e) Kaplan–Meier curves showing 5-year survival of NB patients according to their IL2 (c), IFNG, and TNFB (D), and 
IL4 (e) gene expression normalized with the ratio of actin expression. The NB samples were divided into high- and low-groups based on their upper and lower 
quartile of RNA-seq data. The hazard ratio and P-value displayed on the graphs are from the log-rank test and Gehan–Breslow–Wilcoxon method.
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